Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	e for form 1449A/PT0)		Complete if Known		
15154		D100	I COLUDE	Application Number	10/568,745	
	DRMATION			Filing Date	02-21-06	
STA	TEMENT B	Y AP	PLICANT	First Named Inventor	Mitsuko Ideno	
				Art Unit	1644	
	(Use as many shee	ts as ne	cessary)	Examiner Name	Z. SKELDING	
Sheet	1	of	8	Attorney Docket Number	1422-0709PUS1	

U.S. PATENT DOCUMENTS						
Examiner initial *	Cite	Document Number	Publication Date	Name of Patentee or	Pages, columns, Lines, Where	
muai	No.	Number - Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
	1	US-2003/0022210 - A1	01-30-2003	Bonyhadi et al.		
	2	US-2004/0101519 - A1	05-27-2004	June et al.		
	3	US-2005/227354 - A1	10-13-2005	Sagawa Hiroaki		
	4	US-6,472,204 - B1	10-29-2002	Asada et al.		

	*					
	·····		****			

				All MARIE to white the Artifician		

	FOREIGN PATENT DOCUMENTS									
Examiner	Cite	Foreign Patent Document	Dishilassias Data	Name of Datasta a se	Pages, columns, Lines, Whe					
Initial *	No. 1	Country ³ Number ⁴ Kind Code (if known) ⁵	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevan Figures Appear					
	5	WO 00/09168-A1	02-24-2000							
	6	WO 01/62895-A2	08-30-2001			1				
	7	WO 03/080817 - A1	02-10-2003							
	8	EP 0409655-A2	01-23-1991			$\Box\Box$				
	9	EP 1424387 - A1	06-02-2004			П				
	10	EP 1666589 - A1	06-07-2006							

Examiner		Date	
Signature		Considered	
- 5	,		

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation design number (optional). 2 See Kinds Codes of USPTO patent Documents. at www.uspto.gov or MPEP 901.04. 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449A/PTC)		Complete if Known		
		-100		Application Number	10/568,745	
	DRMATION			Filing Date	02-21-06	
STA	TEMENT B'	Y AP	PLICANT	First Named Inventor	Mitsuko Ideno	
				Art Unit	1644	
	(Use as many shee	its as ne	cessary)	Examiner Name	Z. SKELDING	
Sheet	2	of	8	Attorney Docket Number	1422-0709PUS1	

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, columns, Lines, Where		
initial *	No.	Number - Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear		

			1				
							
			 				
			<u> </u>				
					İ		
			 				

	FOREIGN PATENT DOCUMENTS									
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, columns, Lines, When					
Initial *	No. 1	Country ³ Number ⁴ Kind Code (if known) ⁵	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear					
	11	JP 2003-80817 - A	03-19-2003			П				
	12	WO 2004-018667 - A1	03-04-2004							
	13	WO 2005/019450 - A1	03-03-2005			П				
	14	JP 3-284700-A	12-16-1991			П				
	15	JP 3-80076-A	04-04-1991							
	16	JP 5-271291-A	10-19-1993			П				

Examiner Signature	Date Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assisstance in completing the form, call 1-800-PTO-9199 (1-800-786.9199) and select option 2.

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation design number (optional). 2 See Kinds Codes of USPTO patent Documents. at www.uspto.gov or MPEP 901.04. 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTC)		Complete if Known			
13:150	DILATION	D.O.O.	V COURT	Application Number	10/568,745		
	RMATION			Filing Date	02-21-06		
STAT	LEMENT B	Y AP	PLICANT	First Named Inventor	Mitsuko Ideno		
				Art Unit	1644		
	(Use as many shee	ts as ne	cessary)	Examiner Name	Z. SKELDING		
Sheet	3	of	8	Attorney Docket Number	1422-0709PUS1		

U.S. PATENT DOCUMENTS							
Examiner initial *	Cite	Document Number	Publication Date	Name of Patentee or	Pages, columns, Lines, Where		
miliai	No.	Number - Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear		
					· · · · · · · · · · · · · · · · · · ·		

		<u></u>		A-44-W-2-74			
			-				
				www.			

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	D. H. C. C. C. D. L.	N (D)	Pages, columns, Lines, Whe			
Initial *	No. 1	Country ³ Number ⁴ Kind Code (if known) ⁵	Number ⁴ Kind Code (if known) ⁵ Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
	17	WO 97/01194 - A1	01-09-1997			T		
	18	WO 97/11694 - A1	04-03-1997			T		
	19	WO 99/33863-A1	07-08-1999			T		
						T		
						T		
						T		

Examiner	Date	
Signature	Considered	
	1	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include copy of this form with next communication to applicant. 1. Applicant's unique citation design number (optional). 2 See Kinds Codes of USPTO patent Documents. at www.uspto.gov or MPEP 901.04. 3. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

Substitute for	form 1449B/PTO			Complete if Known			
INFOE	MATION D	ופרו	OSLIDE	Application Number	10/568,745		
	EMENT BY			Filing Date	02-21-06		
SIAII	LIVILIAI DI	AFF	LICANI	First Named Inventor	Mitsuko Ideno		
(U.	se as many sheets a	as neces	sarv)	Art Unit	1644		
	,			Examiner Name	Z. SKELDING		
Sheet	4	of	8	Attorney Docket Number	1422-0709PUS1		

		NON PATENT LITERATURE DOCUMENTS	
Examiner initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	20	"Animal Cell Culture: A Practical Approach", Edited by R.I. Freshney, IRL Press, Oxford, Washington, D.C., 1986, pp. 26-41	
	21	ANIMAL CELL CULTURE METHODS, edited by R. Freshney, Moscow, "Mir", 1989, pages 44, 53, 77 (the original English "Animal Cell Culture - A Practical Approach"), edited by R.I. Freshney, IRL Press, Oxford, Washington, D.C.	
	22	BENIGNI, Febio et al.; Phenotype and Homing of CD4 Tumor-Specific T Cells is Modulated by Tumor Bulk; The Journal of Immunology; 2005, 175, pp. 739-748.	
	23	DARDALHON et al., "Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector," Blood, Vol. 96, No. 3, 2000, pp. 885-893.	
	24	FUNARO et al., "Stimulation of T Cells via CD44 Requires Leukocyte-Function-Associated Antigen Interactions and Interleukin-2 Production", Human Immunology, Vol. 40, 1994, pps. 267-278	
	25	GATTINONI et al., "Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells," J. Clin. Invest., Vol. 115, No. 6, 2005, pp. 1616-1626.	
	26	HALVORSON et al., "alpha4 and alpha5 integrins costimulate the CD3-dependent proliferation of fetal thymocytes," Cell. Immunol., Vol. 189, No. 1, 1998, pp. 1-9.	
	27	HIBINO et al., "Tenascin Suppresses CD3-Mediated T Cell Activation", Biochemical and Biophysical Research Communications, Vol. 250, 1998, pp. 119-124.	
	28	IDENO et al., "RetroNectin® Kumiawaseta T Saibo Kakudai Baiyo (II): Kakudai Baiyo sareta T Saibo Shudan wa NaiveT-yo Saibo no Hiritsu ga Takaku, Takai Kogen Nishikino o Hakki," Dai 65 Kai Annual Meeting of the Japan Cancer Assocation Kiji, 2006, pp. 330.	
	29	IDENO et al., "Soshikitai Human Fibronectin Fragment Shigeki ni yoru Kasseika CTL no Tairyo Expansion-ho," Dai 62 Kai Annual Meeting of the Japan Cancer Association Kiji, 2003, pp. 175.	

,		
Examiner	Date	
Signature	Considered	
=	l	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{1.} Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for	form 1449B/PTO			Complete if Known			
INEOE	RMATION E	Neci	OSLIDE	Application Number	10/568,745		
				Filing Date	02-21-06		
STATEMENT BY APPLICANT				First Named Inventor	Mitsuko Ideno		
(U.	se as many sheets	as neces	sarv)	Art Unit	1644		
			,,	Examiner Name	Z. SKELDING		
Sheet	5	of	8	Attorney Docket Number	1422-0709PUS1		

item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. International Search Report in International Application No. PCT/JP02/08298 mailed December 3, 2002 JPO International Search Report, Appl. No. PCT/JP2006/315881, October 10, 2006 JPO International Search Report, Appl. No. PCT/JP2006/319105, January 9, 2007 Kim YOUNG-JUNE et al., "4-1BB Costimulation Promotes Human T Cell Adhesion to Fibronectin", Cellular Immunology 192, 13-23 (1999) KOBERDA et al., "Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res. Clin. Oncol., Vol. 119, 1993, pp. 131-136. MATSUYAMA et al., "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. 131-3148. MIKAMO, "Bulk Culture of Human Lymphocytec", Cell Toehnology, 1005, 14:3, 233-237. Not in English Language MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English			NON PATENT LITERATURE DOCUMENTS	
JPO International Search Report, Appl. No. PCT/JP2006/315881, October 10, 2006 JPO International Search Report, Appl. No. PCT/JP2006/319105, January 9, 2007 Kim YOUNG-JUNE et al., "4-1BB Costimulation Promotes Human T Cell Adhesion to Fibronectin", Cellular Immunology 192, 13-23 (1999) KOBERDA et al., "Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res. Clin. Oncol., Vol. 119, 1993, pp. 131-138. MATSUYAMA et al., "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. 1133-1148. MIKAMO, "Bulk Culture of Human Lymphocytes", Cell Technology, 1905, 14:3, 323-327. Not in English Language MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English			item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
JPO International Search Report, Appl. No. PCT/JP2006/319105, January 9, 2007 Kim YOUNG-JUNE et al., "4-1BB Costimulation Promotes Human T Cell Adhesion to Fibronectin", Cellular Immunology 192, 13-23 (1999) KOBERDA et al., "Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res. Clin. Oncol., Vol. 119, 1993, pp. 131-136. MATSUYAMA et al., "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. 1133-1148. MIKAMO, "Bulk Culture of Human Lymphosytes", Cell Technology, 1995, 14:3, 233-327. Not in English Language MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English		30	International Search Report in International Application No. PCT/JP02/08298 mailed December 3, 2002	
Kim YOUNG-JUNE et al., "4-1BB Costimulation Promotes Human T Cell Adhesion to Fibronectin", Cellular Immunology 192, 13-23 (1999) KOBERDA et al., "Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res. Clin. Oncol., Vol. 119, 1993, pp. 131-136. MATSUYAMA et al., "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. 1133-1148. MIKAMO, "Bulk Culture of Human Lymphosytes", Cell Tochnology, 1995, 14:2, 232-237. Not in English Language MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English		31	JPO International Search Report, Appl. No. PCT/JP2006/315881, October 10, 2006	
Cellular Immunology 192, 13-23 (1999) KOBERDA et al., "Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res. Clin. Oncol., Vol. 119, 1993, pp. 131-136. MATSUYAMA et al., "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. 1133-1148. MIKAMO, "Bulk Culture of Human Lymphosytes", Coll Technology, 1995, 14:3, 233-227. Not in English Language MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English		32	JPO International Search Report, Appl. No. PCT/JP2006/319105, January 9, 2007	
transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res. Clin. Oncol., Vol. 119, 1993, pp. 131-136. MATSUYAMA et al., "Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. 1133-1148. MIKAMO, "Bulk Culture of Human Lymphocytos", Coll Technology, 1995, 14:3, 233-237 Not in English Language MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English	ann an an Air Saine, a bha ann ath air an Airlia ann an Airlia ann	33		
mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp. MIKAMO, "Bulk Culture of Human Lymphosytes", Cell Technology, 1995, 14:2, 233-227 36 Not in English Language MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English	unumum un en	34	transforming growth factor B inhibition of lymphokine-activated killer cell generation," J. Cancer Res.	
36 Not in English Language MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English		35	mediated by the VLA-5 fibronectin receptor complex," J. Exp. Med., Vol. 170, No. 4, 1989, pp.	
Not in English Language MOSHER, Deane F., Fibronectin, Academic Press Inc., 1-24, authored by Deane F. Mosher, published in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English	000000000000000000000000000000000000000		MW AMO. "Bulk Cultura of Human Lymphondos". Call Tachpology. 1005, 14:2, 222, 227	***************************************
37 in 1988. MURAKI et al., "Retronectin® Kumiawaseta T Saibo Kakudai Baiyo (I): Kakudai Baiyo ga Anteika shi, NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English		36	5,,,,	
NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association Kiji, 2006, pp. 330. Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English		37		
		38	NaiveT-yo Saibo ga Kohiritsu de Zoshoku," Dai 65 Kai Annual Meeting of the Japan Cancer Association	
39 uansiauon.		39	Office Action in Chinese Application No. 200480024172.7 mailed January 15, 2010, including English translation.	

Examiner		Date	
Signature		Considered	
1 -	1	1	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{1.} Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time willt vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for	form 1449B/PTO			Complete if Known			
INFOE	RMATION D	اعدا	OSLIDE	Application Number	10/568,745		
	EMENT BY			Filing Date	02-21-06		
SIAII	EMENIDI	AFF	LICANI	First Named Inventor	Mitsuko Ideno		
(U	se as many sheets a	s neces	sarv)	Art Unit	1644		
	(,		,,	Examiner Name	Z. SKELDING		
Sheet	6	of	8	Attorney Docket Number	1422-0709PUS1		

		NON PATENT LITERATURE DOCUMENTS	
Examiner initial *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т 2
	40	Office Action in Chinese Application No. 200480024172.7 mailed November 30, 2007, including English translation.	
	41	RAO, W. H. et al, "Potent Costimulation of Effector T Lymphocytes by Human Collagen Type I," J Immunol, 2000, vol. 165, pp. 4935-4940	L
	42	Retronectin, 2010, Takara Bio. Inc., http://catalog.takara-bio.co.jp/en/PDFFiles/T100A_B_e.pdf.p.1-8	
	43	SAGAWA et al., "Ko-CD3 Kotai to RetroNectin??o Kumiawaseru Koto ni yoru LAK Saibo Inyu Ryoho no Kairyo," Dai 62 Kai Annual Meeting of the Japan Cancer Association Kiji," 2003, pp. 438.	
	44	SEKINE, "Expansion of Lymphocytes by Culture with Immobilized Anti-CD3 Monoclonal Antibody and Interleukin-2 for Use in Adoptive Immunotherapy of Cancer Patients", Saibo Baiyo (Cell Culture), Vol. 17, No. 6, 1991, pp. 192-195.	
	45	SHUQIN et al., "Induction of Allogenic Cytotoxic T Lymphocytes and Their Culture", Journal of South China Normal University (Natural Science Edition), No. 4, 1994, pp. 11-17 (including partial English language translation)	
	46	SIMON, Markus M. et al., The outer surface lipoprotein A of Borrelia burgdorferi provides direct and indirect augmeting/co-stimulatory signals for the activation of CD4+ and CD8+ T cells", Immunol. Lett., 1995, Vol. 46, No. 3, pp. 137-142.	
	47	STOHL et al., "Generation of Cytolytic Activity with Anti-CD3 Monoclonal Antibodies Involves Both IL-2-Independent and -Dependent Components", J. Immunol., Vol. 144, No. 10, May 15, 1990, pp. 3718-3725	
Marie Control	48	STURM, A., et al, "Dual Function of the Extracellular Matrix: Stimulatory for Cell Cycle Progression of Naive T Cells and Antiapoptotic for Tissue-Derived Memory T Cells," The Journal of Immunology, 2004, vol. 173, pp. 3889-3900	
	49	Supplementary European Search Report issued by the EPO in corresponding European Application No. 06782667.7 on September 16, 2009.	

Examiner		Date	
Signature		Considered	
Signature		Considered	
	l_,	L	I

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{1.} Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for	form 1449B/PTO			Complete if Known				
INFOE	RMATION D	ISCI	OSLIDE	Application Number	10/568,745			
				Filing Date	02-21-06			
SIAII	STATEMENT BY APPLICANT		First Named Inventor	Mitsuko Ideno				
a i	se as many sheets a	s neces	sarv)	Art Unit	1644			
	oo do many oncoio d			Examiner Name	Z. SKELDING			
Sheet	7	of	8	Attorney Docket Number	1422-0709PUS1			

		NON PATENT LITERATURE DOCUMENTS						
Examiner initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	50	TAKAYAMA et al., "Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial", The Lancet, Vol. 356, 2000, pp. 802-807						
	51	US Office Action for Application No. 10/344,534, dated November 6, 2009						
	52	US Office Action for Application No. 10/344,534, mailed May 13, 2008						
	53	US Office Action for Application No. 10/344,534, November 24, 2009						
98/9-110-110-100-101-1-0-1-1-0-1-1-0-1-1-0-1-1-0-1-1-0-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	54	US Office Action for Application No. 10/486,512, dated June 25, 2004						
	55	US Office Action for Application No. 10/509,055, dated May 11, 2007						
	56	US Office Action for Application No. 10/509,055, mailed February 10, 2011						
	57	US Office Action, dated August 31, 2010, for US Application No. 11/990,443	L					
A 4	58	US Office Action, dated December 28, 2010, for US Application No. 11/992,661						
	59	US Office Action, dated February 10, 2011, for US Application No. 10/509,055						

Examiner		Date	
Signature	'	Considered	
(

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{1.} Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known		
				Application Number	10/568,745	
				Filing Date	02-21-06	
				First Named Inventor	Mitsuko Ideno	
(U:	se as many sheets a	s neces	sarv)	Art Unit	1644	
(**************************************				Examiner Name	Z. SKELDING	
Sheet	8	of	8	Attorney Docket Number	1422-0709PUS1	

NON PATENT LITERATURE DOCUMENTS						
Examiner initial *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2			
	60	US Office Action, dated July 6, 2011, for US Application No. 10/509,055				
	61	US Office Action, dated June 9, 2011, for US Application No. 11/992,661				
	62	US Office Action, dated March 16, 2011, for US Application No. 11/990,443	L			
	63	US Office Action, dated October 14, 2010, for US Application No. 11/992,661				
	64	WHITESIDE et al., "Isolation of Human NK Cells and Generation of LAK Activity, Current Protocols in Immunology", 1996, Supp. 17, Unit 7.7, pages 7.7.1-7.7.11.	E			
	65	WILLIAMS et al., "Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions," Letters to Nature, Vol. 352, 1991, pp. 438-441				
	66	WILLS, M. R., et al, "Identification of Naive or Antigen-Experienced Human CD8+ T Cells by Expression of Costimulation and Chemokine Receptors: Analysis of the Human Cytomegalovirus-Specific CD8+ T Cell Response," The Journal of Immunology, 2002, vol. 168, pp. 5455-5464				
	67	ZHOU et al., "Molecular Mechanisms Underlying Differential Contribution of CD28 Versus Non-CD28 Costimulatory Molecules to IL-2 Promoter Activation," The Journal of Immunology, Vol. 168, 2002, pp. 3847-3854				

Examiner Signature /Zachary Skelding/	Date Considered	08/30/2011
---------------------------------------	--------------------	------------

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{1.} Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.